相关实验视频

Updated: Jul 9, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

对于所有AML患者,HMA加VEN的方法,有或没有BMT

Heather J Male¹, Tara L Lin¹

¹University of Kansas Medical Center, Division of Hematologic Malignancies and Cellular Therapeutics, Kansas City, KS.

Hematology. American Society of Hematology. Education Program

|December 9, 2023

概括

新的治疗组合,包括含有venetoclax的低甲基化剂,正在改善急性髓性白血病 (AML) 患者的生存率. 进一步的研究正在探索它们在年轻患者和干细胞移植前的使用.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

急性髓性白血病 (AML) 治疗格局已经发生了显著的变化.
新型治疗方案为以前无法接受抗瘤治疗的患者提供了新的选择.

研究的目的:

为了评估低甲基化剂-维内托克拉克斯 (HMA-VEN) 组合的疗效.
探索HMA-VEN在AML治疗中的不断扩大的作用,包括在不同的患者群体和环境中.

主要方法:

与单独使用HMA相比,对使用HMA-VEN的患者结局的回顾性分析.
目前正在进行的前性研究,研究HMA-VEN在适合患者和作为前原性干细胞移植 (SCT) 方案中的情况.

主要成果:

在老年,不适合的AML患者中,HMA-VEN证明改善了整体存活率,而不是HMA单疗法.
追溯数据表明,HMA-VEN在某些人群中比密集化疗 (IC) 有潜在的好处.
在回顾性研究中,在SCT之前观察到HMA-VEN的可行性和可测量的残留疾病负面影响.

结论:

对于老年/不适合的AML患者来说,HMA-VEN代表了重大进展.
需要进一步的前性试验来确认HMA-VEN在适合患者中的作用,并作为SCT前的策略.
HMA-VEN的分散交付扩大了访问,但SCT的协作仍然至关重要.

更多相关视频

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...